In Brief

In Brief

In Brief

In Brief

Research Highlight

A new class of AR antagonists? A new class of AR antagonists?, Published online: 21 January 2019; doi:10.1038/s41585-019-0147-9 A new class of AR antagonists?

Clarifying the link between ibuprofen and hypogonadism Clarifying the link between ibuprofen and hypogonadism, Published online: 21 January 2019; doi:10.1038/s41585-019-0146-x Clarifying the link between ibuprofen and hypogonadism

Hyperpolarized MRI illustrates metabolic response to therapy Hyperpolarized MRI illustrates metabolic response to therapy, Published online: 03 January 2019; doi:10.1038/s41585-018-0139-1 Hyperpolarized MRI illustrates metabolic response to therapy

Salvage prostatectomy for recurrent disease Salvage prostatectomy for recurrent disease, Published online: 07 January 2019; doi:10.1038/s41585-018-0143-5 The long-term outcomes of the first prospective, multi-institutional, single-arm study of patients with prostate cancer treated with salvage radical prostatectomy after disease recurrence following radiotherapy have recently been published. Durable oncological control was reported, possibly because most patients had low-risk or intermediate-risk prostate cancer at initial diagnosis and the biochemical progression-free survival interval was long.

ERCC2 mutations drive cisplatin sensitivity ERCC2 mutations drive cisplatin sensitivity, Published online: 18 December 2018; doi:10.1038/s41585-018-0141-7 ERCC2 mutations drive cisplatin sensitivity

Reviving regenerative urology Reviving regenerative urology, Published online: 13 December 2018; doi:10.1038/s41585-018-0131-9 Despite initial enthusiasm, poor translation of preclinical studies and high-profile scandals involving stem cell research have hindered the field of regenerative urology in recent years. However, consideration of the potential of regenerative approaches to revolutionize patient care ought to reignite interest and begin a renaissance in regenerative urology research.

Combination therapy for advanced and metastatic kidney cancer Combination therapy for advanced and metastatic kidney cancer, Published online: 11 December 2018; doi:10.1038/s41585-018-0133-7 The treatment of metastatic kidney cancer is rapidly evolving with the shift from immune checkpoint inhibitor monotherapy to combination therapy. In 2018, the combination of nivolumab–ipilimumab received regulatory approval and multiple positive clinical trials were reported with combinations of PD-1 or PD-L1 inhibitors in conjunction with antiangiogenic drugs.

Efficacy of a novel single-dose oral antibiotic for urogenital gonorrhoea Efficacy of a novel single-dose oral antibiotic for urogenital gonorrhoea, Published online: 04 December 2018; doi:10.1038/s41585-018-0130-x Efficacy of a novel single-dose oral antibiotic for urogenital gonorrhoea

From EMUC18 From EMUC18, Published online: 26 November 2018; doi:10.1038/s41585-018-0128-4 From EMUC18

Penile traction therapy — efficacy in PD Penile traction therapy — efficacy in PD, Published online: 14 November 2018; doi:10.1038/s41585-018-0125-7 Penile traction therapy — efficacy in PD

TECs support the SSC niche TECs support the SSC niche, Published online: 14 November 2018; doi:10.1038/s41585-018-0123-9 TECs support the SSC niche

eCoin device stops patients from spending a penny eCoin device stops patients from spending a penny, Published online: 13 November 2018; doi:10.1038/s41585-018-0124-8 eCoin device stops patients from spending a penny

Mismatch mutations: aggressive but sensitive Mismatch mutations: aggressive but sensitive, Published online: 24 October 2018; doi:10.1038/s41585-018-0113-y Mismatch mutations: aggressive but sensitive

Mirabegron MIRACLE cure for male incontinence? Mirabegron MIRACLE cure for male incontinence?, Published online: 24 October 2018; doi:10.1038/s41585-018-0115-9 Mirabegron MIRACLE cure for male incontinence?

MicroRNA signature aids diagnosis MicroRNA signature aids diagnosis, Published online: 24 October 2018; doi:10.1038/s41585-018-0114-x MicroRNA signature aids diagnosis

AR variants in CTCs correlate with outcomes AR variants in CTCs correlate with outcomes, Published online: 24 October 2018; doi:10.1038/s41585-018-0116-8 AR variants in CTCs correlate with outcomes